

Peripheral Nervous System Complications of Immunotherapy in Cancer Patients

Mary Jane Lim-Fat, MD, MSc, FRCPC

Neuro-Oncologist, CNS Site Lead, Odette Cancer Centre

Sunnybrook Health Sciences Centre

Assistant Professor, Department of Medicine

University of Toronto

Disclosures

- Honoraria from Servier, Chimerix, Novocure

Learning Objectives

1. Explain the immunological mechanisms by which immune checkpoint inhibitors lead to neuropathic injury

Learning Objectives

2. Recognize and differentiate the spectrum of peripheral nervous system toxicities—such as inflammatory neuropathies, neuromuscular junction disorders, and myositis—in patients treated with immune checkpoint inhibitors

Learning Objectives

3. Develop evidence-based management plans for immunotherapy-related PNS complications, including diagnostic workup, immunosuppressive therapies, and strategies for therapy modification or rechallenge

Key Message

- Immune checkpoint inhibitors can induce diverse peripheral nervous system toxicities through off-target immune activation
- Prompt recognition, accurate diagnosis, and timely immunomodulatory treatment are essential to mitigate neurological morbidity while maintaining effective cancer therapy